Imugene Limited (IMU.AX)

0.0970 +0.0030 (+3.19%) At close: 04:10PM AEDT

Imugene Limited

4-6 Bligh Street
Suite 12.01, Level 12
Sydney, NSW 2000
Australia
61 2 9423 0881
https://www.imugene.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD	Executive Chairman	316.1k	N/A	1956
Ms. Leslie Chong	CEO, MD & Executive Director	1.05M	N/A	N/A
Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD	CFO & Company Secretary	424.28k	N/A	1966
Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.	Head of Corporate Development	489.47k	N/A	N/A
Dr. Monil Shah M.B.A., Pharm.D.	Chief Business Officer	799.2k	N/A	N/A
Dr. Bradley Glover Ph.D.	Chief Operating Officer	N/A	N/A	1969
Ms. Ursula McCurry	Senior Vice President of Clinical Operations	N/A	N/A	N/A
Dr. John Byon	Senior Vice President of Clinical Development	N/A	N/A	N/A
Dr. Joseph Paul Woodard Jr., M.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in phase 2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling and is in phase I trial; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a collaboration with Arovella Therapeutics Ltd to test the integration of Arovella's CAR19- iNKT cell therapy with the onCARlytics platform, as well as a research collaboration with RenovoRx, Inc. to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Corporate governance

Imugene Limited’s ISS governance QualityScore as of 1 December 2023 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.